第 48 卷第 3 期 Vol. 48 No. 3 2018 年 6 月 Jun 2018

所属栏目：专论与综述 JAK抑制剂在类风湿性关节炎治疗中的研究进展

张溢凡 （中国人民解放军93575部队 卫生队，河北 承德 067000）

摘　要：Janus激酶（JAK）是一种非受体酪氨酸蛋白激酶，参与体内众多重要的生物学过程，是一条重要的细胞内信号转导通路。研究表明，由其介导的通路通常与炎症性疾病、皮肤性疾病及其他自身免疫性疾病有关，JAK已逐渐成为治疗这些疾病的重要靶标。主要综述了JAK的结构与功能、JAK-STAT信号通路在治疗RA中的调控作用以及近年来JAK抑制剂的研究进展，旨在为以JAK为靶点的药物研发提供参考。

关键词：JAK抑制剂；类风湿性关节炎（RA）；研究进展

中图分类号：R971　　文献标识码：B　　文章编号：1009-9212（2018）03-0010-05

Research Progress of JAK Inhibitors in the Treatment of Rheumatoid Arthritis

ZHANG Yi-fan (Health Unit of 93575 Troop, People's Liberation Army of China, Chengde 067000, China)

Abstract：Janus kinase (JAK), a non-receptor tyrosine kinase, participated in many important biological processes in vivo and was an important intracellular signal transduction pathway. It was observed that the pathways mediated by JAKs were associated with inflammatory diseases, dermatologic diseases, and other autoimmune diseases, and JAKs were the important targets for the treatment of these diseases. This review mainly discussed the structure and function of JAKs, and the role of the JAK-STAT signaling pathway in treating RA. Meanwhile, the development of JAK inhibitors in recent years was also described, focusing on providing effective reference for researching new drugs based on JAK.

Key words：JAK inhibitor; rheumatoid arthritis (RA); research progress

作者简介：张溢凡（1991-），男，河南郑州人，药师，主要从事生物技术研究（E-mail：149889071@qq.com）。

收稿日期：2018-06-12